---
input_text: 'Relapse following withdrawal of D-penicillamine from combination (D-penicillamine
  + zinc) therapy in hepatic Wilson disease. OBJECTIVES: Long-term D-penicillamine
  (D-pen) therapy in Wilson disease (WD) has numerous adverse effects which advocates
  its withdrawal, but with an inherent risk of relapse. This prospective observational
  study was conducted with the objective of evaluating incidence of relapse following
  withdrawal of D-pen from combination (D-pen + zinc) therapy in maintenance phase
  of previously symptomatic hepatic WD. METHODS: Hepatic WD patients <18 years of
  age and on combination therapy for >2 years with 6 months of biochemical remission
  were included. Biochemical remission was defined as achievement of (i) aspartate
  aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 times upper limit
  of normal (ULN), (ii) serum albumin >3.5 g/dL, international normalized ratio (INR)
  <1.5 and (iii) 24-h urinary copper excretion (UCE) <500 mcg/day, nonceruloplasmin-bound-copper
  (NCC) <15 mcg/dL. After D-pen withdrawal, monthly liver function test (LFT) and
  INR and 3 monthly UCE and NCC were done till 1 year or relapse (elevation of AST/ALT/both
  >2 times ULN or total bilirubin >2 mg/dL), whichever occurred earlier. RESULTS:
  Forty-five patients enrolled with median combination therapy duration of 36 months.
  Sixty percent of them had their index presentation as decompensated cirrhosis. Fourteen
  patients (31.8%) relapsed (cumulative incidence: 4 at 3 months, 11 at 6 months,
  and 14 at 12 months after D-pen discontinuation). All relapsers had index presentation
  as decompensated cirrhosis. On Cox-regression, ALT at D-pen withdrawal was an independent
  predictor of relapse (hazard ratio [HR]: 1.077, 95% confidence interval [CI]: 1.014-1.145,
  p = 0.017) with area under the receiver operating characteristic (AUROC) of 0.860.
  ALT >=40 U/L predicted risk of relapse with 85.7% sensitivity, 70.9% specificity.
  CONCLUSION: Incidence of relapse after withdrawal of D-pen from combination therapy
  is 31.8% in hepatic WD. ALT >=40 U/L, at the time of D-pen stoppage, predicts future
  relapse.'
raw_completion_output: |-
  primary_disease: Hepatic Wilson Disease
  medical_actions: Withdrawal of D-penicillamine; Combination therapy (D-penicillamine + zinc); Monthly liver function test; 3 monthly urinary copper excretion and nonceruloplasmin-bound-copper measurement
  symptoms: Decompensated cirrhosis; Elevation of AST/ALT/both >2 times ULN; Total bilirubin >2 mg/dL
  chemicals: D-penicillamine; Zinc; Aspartate aminotransferase (AST); Alanine aminotransferase (ALT); Serum albumin; International normalized ratio (INR); 24-h urinary copper excretion (UCE); Nonceruloplasmin-bound-copper (NCC)
  action_annotation_relationships: Withdrawal of D-penicillamine (with D-penicillamine) PREVENTS Decompensated cirrhosis IN Hepatic Wilson Disease; Combination therapy (D-penicillamine + zinc) TREATS Decompensated cirrhosis IN Hepatic Wilson Disease; Monthly liver function test MONITORS Decompensated cirrhosis IN Hepatic Wilson Disease; 3 monthly urinary copper excretion and nonceruloplasmin-bound-copper measurement MONITORS Decompensated cirrhosis IN Hepatic Wilson Disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  3 monthly urinary copper excretion and nonceruloplasmin-bound-copper measurement MONITORS Decompensated cirrhosis IN Hepatic Wilson Disease

  ===

extracted_object:
  primary_disease: Hepatic Wilson Disease
  medical_actions:
    - Withdrawal of D-penicillamine
    - Combination therapy (D-penicillamine + zinc)
    - Monthly liver function test
    - 3 monthly urinary copper excretion and nonceruloplasmin-bound-copper measurement
  symptoms:
    - Decompensated cirrhosis
    - Elevation of AST/ALT/both >2 times ULN
    - Total bilirubin >2 mg/dL
  chemicals:
    - CHEBI:7959
    - CHEBI:27363
    - CHEBI:76649
    - CHEBI:37708
    - Serum albumin
    - International normalized ratio (INR)
    - 24-h urinary copper excretion (UCE)
    - Nonceruloplasmin-bound-copper (NCC)
  action_annotation_relationships:
    - subject: Withdrawal of D-penicillamine
      predicate: PREVENTS
      object: Decompensated cirrhosis
      qualifier: Hepatic Wilson Disease
      subject_qualifier: with D-penicillamine
      subject_extension: CHEBI:7959
    - subject: Combination therapy
      predicate: TREATS
      object: Decompensated cirrhosis
      qualifier: Hepatic Wilson Disease
      subject_extension: D-penicillamine + zinc
    - subject: Monthly liver function test
      predicate: MONITORS
      object: Decompensated cirrhosis
      qualifier: Hepatic Wilson Disease
    - subject: <3 monthly urinary copper excretion and nonceruloplasmin-bound-copper
        measurement>
      predicate: <MONITORS>
      object: <Decompensated cirrhosis>
      qualifier: <Hepatic Wilson Disease>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <urinary copper excretion and nonceruloplasmin-bound-copper
        measurement>
      object_extension: <>
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0001695
    label: cardiac arrest
  - id: HP:0001685
    label: myocardial fibrosis
  - id: HP:0001663
    label: ventricular fibrillation
  - id: CHEBI:30703
    label: tetrathiomolybdate (TTM)
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0006554
    label: acute liver failure
  - id: HP:0003256
    label: coagulopathy
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: CHEBI:28694
    label: Copper
  - id: HP:0001395
    label: Liver fibrosis
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:39501
    label: trientine
  - id: CHEBI:27363
    label: zinc
  - id: HP:0001410
    label: hepatic dysfunction
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0000376
    label: Liver biopsy
  - id: HP:0001404
    label: Hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:50868
    label: Penicillamine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0001541
    label: ascites
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0001347
    label: Hyperreflexia
  - id: HP:0031843
    label: Bradyphrenia
  - id: HP:0002362
    label: Shuffling gait
  - id: HP:0002300
    label: Mutism
  - id: HP:0001621
    label: Hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: Pramipexole
  - id: CHEBI:2618
    label: Amantadine
  - id: HP:0001399
    label: liver failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: HP:0001342
    label: Intracerebral Hemorrhage
  - id: MAXO:0000533
    label: Molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002344
    label: worsening neurological symptoms
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0012896
    label: abnormal motor evoked potentials (MEPs)
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:8830
    label: rhodanine
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (t-AML or AML-MRC)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: CHEBI:37404
    label: Elemental copper
  - id: CHEBI:16856
    label: Plasma glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: CHEBI:33697
    label: RNAs
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: Dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: HP:0001250
    label: Epileptic seizures
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002315
    label: Headache
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:166831
    label: copper chelating agents
  - id: MONDO:0004789
    label: Cholangitis
  - id: MAXO:0010026
    label: zinc supplementation
  - id: CHEBI:16796
    label: Melatonin
  - id: MAXO:0009095
    label: Zinc (Zn) therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:38161
    label: Chelator
  - id: MONDO:0019542
    label: Acute Liver Failure (ALF)
  - id: HP:0002204
    label: Pulmonary embolism
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001944
    label: dehydration
  - id: CHEBI:18248
    label: iron
  - id: CHEBI:18291
    label: manganese
  - id: CHEBI:22984
    label: calcium
  - id: HP:0001081
    label: Cholelithiasis
  - id: HP:0002716
    label: Lymphadenopathy
  - id: MONDO:0100193
    label: End-stage liver diseases
  - id: HP:0002040
    label: Esophageal varices
  - id: HP:0100626
    label: End-stage liver diseases
  - id: MONDO:0017014
    label: children
  - id: MAXO:0009016
    label: Botulinum toxin type A (BoNT-A) injection
  - id: CHEBI:3160
    label: Botulinum toxin type A (BoNT-A)
  - id: HP:0003088
    label: Premature osteoarthritis
  - id: HP:0002885
    label: Mallory-Denk body (MDB) formation
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:16990
    label: Bilirubin
  - id: MONDO:0100192
    label: Liver failure
  - id: HP:0001409
    label: Portal hypertension
  - id: HP:0001402
    label: Hepatocellular carcinoma
  - id: CHEBI:30663
    label: Serum ceruloplasmin (CP)
  - id: HP:0001513
    label: obesity
  - id: CHEBI:16610
    label: spermidine
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:15351
    label: AcCoA
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:62984
    label: zinc acetate
  - id: MAXO:0000165
    label: treatment with diuretics
  - id: CHEBI:35498
    label: diuretics
  - id: CHEBI:33281
    label: antibiotics
  - id: CHEBI:50503
    label: laxatives
  - id: CHEBI:76649
    label: Aspartate aminotransferase (AST)
  - id: CHEBI:37708
    label: Alanine aminotransferase (ALT)
